Disclosed are novel α-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation methods thereof, and pharmaceutical compositions for use in an immune adjuvant containing the same as an active ingredient. The derivatives, in which the amide moiety of α-GalCer is bioisosterically replaced with a triazole moiety, direct cytokine secretion toward IL-4 rather than IFN-γ and thus can be used as a therapeutic for autoimmune diseases regulated by IL-4, such as type 1 diabetes and multiple sclerosis.
揭示了新颖的α-半
乳糖鞘氨醇衍
生物,其药用可接受的盐,其制备方法以及用于免疫佐剂的药物组合物,其中包含其作为活性成分。这些衍
生物中,α-半
乳糖鞘氨醇的酰胺基团被三唑基团
生物异构地替代,将细胞因子分泌定向于IL-4而非IFN-γ,因此可以用作治疗由IL-4调节的自身免疫疾病,如1型糖尿病和多发性硬化症。